Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients

SAN FRANCISCO – Early post-transplant brentuximab vedotin dramatically slows Hodgkin’s lymphoma progression in patients at high risk for relapse or progression, the phase III AETHERA study...